Listing & Compliance Notices

CapForce Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 5, 2023, OpGen, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share over the prior 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq’s Listing Rules, the Company has 180 calendar days to regain compliance with Nasdaq’s minimum bid price requirement. If the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if the”

Presidio Property Trust, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 6, 2023, Presidio Property Trust, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 5, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar d”

Golden Minerals Co received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(iii)).

“June 6, 2023, Golden Minerals Company (the “Company”) received written notification (the “Notice”) from the NYSE American LLC (the “NYSE American”) that the Company is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). The Company is required to report a stockholders’ equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Notice noted that the Company reported a stockholders’ equity of $4.1 million as of March 31, 2023, and losses from continuing”

FIREFLY NEUROSCIENCE, INC. received a nasdaq delisting notice notice regarding other (rules 5550(a)(2)).

“n the closing bid price of the Company’s common stock for the 30 consecutive business day period between October 27, 2022 and December 8, 2022, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq’s Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In its December 9, 2022 letter, Nasdaq advised the Company that it would be afforded an additional 180 day compliance period, provided that on the 180th day of the Compliance Period it met the applicable market value of publicly held shares requirement for continued listing and all other”

FIREFLY NEUROSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

“June 2, 2023 to evidence compliance. The Company intends to submit a plan to regain compliance with Nasdaq’s continuing listing requirement for stockholders’ equity, as discussed below. With respect to the June 8, 2023 delisting determination letter, the Company intends to timely request a hearing before the Nasdaq Hearings Panel (the “Panel”) to present its plan for regaining compliance with the required minimum stockholders’ equity, the minimum bid price requirement, and all other applicable listing requirements. The hearing request will stay the suspension and delisting of the Company’s sec”

Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 16, 2023, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported stockholders’ equity of $(236,792), which is below the Stockholders’ Equity Requirement for c”

Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“uirement Deficiency As previously reported, on May 16, 2023, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported stockholders’ equity of $(236,792), which is b”

BiomX Inc. received a nyse_american delisting notice notice regarding other (rules 1001).

“y’s common stock or units. Trading in the Company’s common stock (ticker symbol PHGE) and units (ticker symbol PHGE.U), will continue on the NYSE American. The NYSE justified its determination to commence proceedings to delist the Warrants because they are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company due to the low trading price of the Warrants. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. June 8”

BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding other.

“June 8, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company’s previously announced noncompliance with the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market has been cured. Accordingly, the Compliance Letter provided that the matter has been closed with Nasdaq. The Company’s common stock will continue to be listed and traded on The Nasdaq Global Market. SIGNATUR”

HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“June 6, 2023, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Company's filing for protection under Chapter 11 of the U.S. Bankruptcy Code (the "Filing") and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “Securities”) will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on June 15, 2023 and a Form 25-NSE will be filed with the Securities and”

POLARITYTE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 26, 2022, the Company received a deficiency letter (the “Bid Price Notice”) from the Staff notifying the Company that the Company was not in compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing the Bid Price Notice. Trading of the Company’s common s”

POLARITYTE, INC. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“June 7, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. In addition, as previously disclosed, on October 26, 2022, the Company received a deficiency letter (the “Bid Price Notice”) from the”

Acer Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 5, 2023, Acer Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market under”

TUPPERWARE BRANDS CORP received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“June 1, 2023, Tupperware Brands Corporation (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is not in compliance with Sections 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day per”

TUPPERWARE BRANDS CORP received a nyse deficiency notice notice regarding other (rules 802.01B).

“June 1, 2023, Tupperware Brands Corporation (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is not in compliance with Sections 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day per”

TITAN PHARMACEUTICALS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement”

Global Star Acquisition Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“June 1, 2023, the Company received a letter from Nasdaq indicating that based on the Company’s May 25, 2023 filing of the Form 10-K, the Staff has determined that the Company has complied with the Listing Rule and, accordingly, the matter was closed. As a result, the Company is currently in compliance with the Nasdaq Listing Rules and the Company’s securities will continue to trade on Nasdaq. As previously disclosed in the Notification of Late Filing on Form 12b-25 filed on May 15, 2023 and Amendment No. 1 filed on May 23, 2023 by the Company with the SEC, the Company had determined that it re”

Wejo Group Ltd received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“May 31, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the filing of the Notice of Intent and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common shares and public warrants (collectively, the “Public Securities”) will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s Public Securities will be suspended at the opening of busines”

Nocturne Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5810(b)).

“eport Form 8-K, discloses its receipt of the Public Float Notice in accordance with Nasdaq Listing Rule 5810(b). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto”

EdtechX Holdings Acquisition Corp. II received a nasdaq noncompliance notice notice regarding other (rules 5550(a)(4)).

“n compliance with Listing Rule 5550(a)(4) (the “ Listing Rule ”) because the Company does not have a minimum of 500,000”

ShiftPixy, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“June 5, 2023, ShiftPixy, Inc. (the “Company”) received a letter (the “Nasdaq Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notifies the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(2), which requires that the Company maintain a Market Value of Listed Securities (“MVLS”) of $35 million, and that the Company does not otherwise satisfy the requirements of Listing Rules 5550(b)(1) or 5550(b)(3). The Staff calculates MVLS based upon the most recent Total Shares Outstanding (TSO), multip”

AUDACY, INC. received a nyse delisting notice notice regarding other (rules 802.01D).

“May 16, 2023, the New York Stock Exchange (the “NYSE”) notified Audacy, Inc. (the “Company”) that it had elected to commence proceedings to delist the Company’s Class A common stock (the “Class A common stock”) from the NYSE based on the Company’s “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual (“Section 802.01D”). On May 31, 2023, the Company submitted a written appeal request for a review of the NYSE’s determination by a Committee of the Board of Directors of the NYSE (the “NYSE Committee”). Pursuant to Section 804.00 of the NYSE Listed Company Ma”

RESEARCH FRONTIERS INC received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“May 30, 2023, the Company received a letter from the Nasdaq Stock Market (“Nasdaq”) noting that, in accordance with Nasdaq Listing Rule 5605, the Audit Committee of the Company was required to consist of at least three independent directors in order to satisfy applicable Nasdaq listing requirements. The Company believes that with the appointment of Mr. Peso to the Company’s Audit Committee (which is in addition to his appointment to its Nominating and Corporate Governance Committee), the Company meets the Nasdaq listing requirements as set forth in Nasdaq Listing Rule 5605. Details are noted i”

NAVIDEA BIOPHARMACEUTICALS, INC. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

“June 1, 2023, the Company received a written notice (the “Notice”) from NYSE Regulation (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of Common Stock have been selling for a substantial period of time at a low price per share. The Notice has no immediate effect on the listing or trading of the Company’s Common Stock and the Common Stock will continue to trade on the NYSE American under the symbol “NAVB,” although a “below compliance” i”

DIEBOLD NIXDORF, Inc received a nyse delisting notice notice regarding other (rules 802.01D).

“June 2, 2023, the Company was notified by the NYSE that, as a result of the Chapter 11 Cases and Dutch Scheme Proceedings, and in accordance with Section 802.01D of the NYSE Listed Company Manual, the NYSE has determined to commence proceedings to delist the Company’s common shares from the NYSE. The NYSE also indefinitely suspended trading of the Company’s common shares on June 2, 2023. The NYSE will apply to the Securities and Exchange Commission (the “SEC”) to delist the Company’s common shares upon completion of all applicable procedures. The Company does not intend to appeal the NYSE dete”

Future Health ESG Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).

“June 1, 2023, Future Health ESG Corp. (the “Company”) received a written notice (the “Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company was not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capita”

Healthcare Triangle, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 31, 2023, Healthcare Triangle, Inc. (the “Company”) received a notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has determined the Company did not regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by May 30, 2023, the deadline to regain compliance with the Rule pursuant to the notice the Company received from Nasdaq on December 1, 2022 (the “Extension Notice”), and therefore the”

Beam Global received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“June 2, 2023, the Company notified the NASDAQ Stock Market, LLC that upon Ms. Floyd’s resignation, the Company will no longer be in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to be comprised of a minimum of three independent directors. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A), which cure period will expire within 180 days from Ms. Floyd’s departure. The Company intends to appoint an additional independent director to the Audit Committee of the Bo”

Histogen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 5, 2023, Histogen Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 2, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until De”

AGILE THERAPEUTICS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“(the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders’”

NEKTAR THERAPEUTICS received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“May 26, 2023, Nektar Therapeutics (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Global Select Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”) because the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Com”

FAT PROJECTS ACQUISITION CORP received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C), 5450(b)(2)(A)).

“May 26, 2023, Fat Projects Acquisition Corp, a Cayman Islands exempt company limited by shares, with company registration number 374480 (the “ Company ”), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that since the Market Value of Publicly Held Shares of the Company was less than $15 million for the last 30 consecutive business days, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5450(b)(2)(C) which requires the Company to maintain a Market Valu”

Sagaliam Acquisition Corp received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“April 19, 2023 (the “April 19 Letter”), NASDAQ notified Sagaliam Acquisition Corp. (the “Company”) that the Company no longer met the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Rule”). On May 22, 2023, the Company filed its Form 10-K for the period ended December 31, 2022. On June 1, 2022, NASDAQ notified the Company that based on the May 22, 2023 filing of the Company’s Form 10-K for the period ended December 31, 2022, NASDAQ has determined that the Company complies with the Rule. Accordingly, NASDAQ informed the Company that it considered the”

Marpai, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“May 31, 2023, Marpai, Inc. (the “Company”) received a notification letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Companythat for the last 30 consecutive business days preceding the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum of $35,000,000 required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until November 27, 2023, to regain compliance with the MVLS Requi”

RMG Acquisition Corp. III received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 25, 2023, RMG Acquisition Corp. III (the “Company”) received a delinquency notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Co”

BuzzFeed, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 31, 2023, BuzzFeed, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Requirement ”). The Notice has no effect at this time on the Company’s common stock or warrants, which continue to trade on The Nasdaq”

ARKO Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)(B)).

“June 2, 2023, the Company received a notification from Nasdaq confirming the foregoing and that, as permitted by Nasdaq Listing Rule 5605(c)(4)(B), the Company has until November 1, 2023 to cure this non-compliance. The Company expects to cure this non-compliance prior to November 1, 2023 and has an active search underway to fill the vacancy on the Audit Committee. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARKO Corp. Date: June 2, 2023 By: /s/”

Clene Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 31, 2023, Clene Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing in the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” In accord”

RVL Pharmaceuticals plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 2, 2023, RVL Pharmaceuticals plc (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s ordinary shares, $0.01 nominal value per share (the “Ordinary Shares”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the list”

IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 31, 2023, the Company received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1) because the Company’s stockholders’ equity of $996,955, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the required minimum of $2.5 million, and because, as of May 30, 2023, the Company did not meet the alternative c”

Minerva Neurosciences, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“May 31, 2023, the Company received a second written notice from Nasdaq indicating that, based upon the Company’s continued non-compliance with the Rule, the staff of Nasdaq had determined to delist the Company’s securities from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). As a result, the Company intends to timely request a hearing before the Panel. The hearing request will stay any suspension or delisting action pending the completion of the hearing and the expiration of any additional extension period granted by the Pane”

Glucotrack, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 26, 2023, GlucoTrack, Inc . (the “Company”) received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. Pursuant to Rule 5810(c)(3)(C) if at any time during this 180 day period the closing bid price of the Company’s sec”

ONCOSEC MEDICAL Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 1, 2023, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock, which will continue to trade at this time on the Nasdaq Capital Market under the symbol “ONCS.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar”

Venus Concept Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 31, 2023, Venus Concept Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company’s stockholders’ equity as reported in the Company’s Form 10-Q for the period ended March 31, 2023 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (“Minimum Equity Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days to submit a plan to regain”

Bionano Genomics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 30, 2023, Bionano Genomics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasd”

FEMASYS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 1, 2023, Femasys Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The Company has 180 calendar days, or until November 28, 2023, to regain compliance with the Minimum Bid Price Require”

Mobiquity Technologies, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“June 1, 2023, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the “ Panel ”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the minimum stockholders’ equity requirement. In the interim, the Company’s comm”

M3-Brigade Acquisition III Corp. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“May 23, 2023, the Company received a notice (the “Notice”) from the NYSE Regulation staff of the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual (the “Rule”) because it has not timely filed the Form 10-Q with the SEC. The Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities”

ST Energy Transition I Ltd. received a nyse delisting notice notice regarding other (rules 802.01D).

“alue $0.0001 per share (the “Class A Shares”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “STET WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Class A Shares and SAIL SM securities will continue on the NYSE. Cautionary Statement Regarding Forward-Looking Statements This report includes “forward-looking stateme”

Sagaliam Acquisition Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“November 22, 2023 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the Company’s MVLS must equal or exceed $50 million for a minimum of 10 consecutive business days at any time prior to the Compliance Date. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter. In the event that the Company does not regain compliance with the MVLS Rule by the Compliance Date, it will receive written notification that its securities are subject to delisting. At that time”